• Home News Cumberland Pharmaceuticals To Announce First Quarter 2020 Financial Results

Cumberland Pharmaceuticals To Announce First Quarter 2020 Financial Results

Posted 16 May-2020 08:41 PM by Kevin | 1249

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2020 financial results and a Company update after the market closes on Wednesday, May 20, 2020. A conference call and live Internet webcast will be held on Wednesday, May 20, 2020 at 4:30 p.m. Eastern Time to discuss the results.

To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The conference ID for the rebroadcast is 1692495. The live webcast and rebroadcast can be accessed via Cumberland's

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high quality prescription brands to improve patient care. The Company develops, acquires and commercializes brands for the hospital acute care, gastroenterology and oncology market segments. These medical specialties are categorized by moderately concentrated prescriber bases that Cumberland believes can be penetrated effectively by targeted sales forces. The Company's portfolio of FDA approved brands includes:

  • Acetadote® (acetylcysteine) Injection, for the treatment of acetaminophen poisoning;
  • Caldolor® (ibuprofen) Injection, for the treatment of pain and fever;
  • Kristalose® (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;
  • Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;
  • Vaprisol® (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
  • Vibativ® (telavancin) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
  • RediTrex® (methotrexate) Injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis.

For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company's website

The Company has Phase II clinical programs underway evaluating its ifetroban product candidates in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy ("DMD"), Systemic Sclerosis ("SSc"), and Aspirin-Exacerbated Respiratory Disease ("AERD"), Hepatorenal Syndrome ("HRS") and Portal Hypertension ("PH").

Source

https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-first-quarter-2020-financial-results-301060309.html


Tags:

Hepatorenal Syndrome,RediTrex,Press Release , Press Release Power USA, Press Release Power Nashville , Financial Press Release ,Cumberland Pharmaceuticals Inc, Cumberland Press Release,Vibativ,Vaprisol® Affordable Press Release Website, Affordable Press Release Distribution Site, Free Press Release Website, Free Press Release Distribution, Press Release

Company Information

Company Name Contact Person Contact Number Email Id Website Address
Cumberland Pharmaceuticals 8772747200 info@cumberlandpharma.com http://www.cumberlandpharma.com/

Other Finance Related Press Release News

Morgan Financial Recovery helps clients recover their money Free

Financial frauds are increasing on a daily basis and every day, some new kind of scam is being unearthed by the investigative agencies. Scammers, owin...Read More


Newly Approved Massachusetts Bill Streamlines HECM/Reverse Mortgage Counseling via Telephone and Online Video Free

Seniors can now access Housing Wealth during COVID-19. A new law signed by Governor Charlie Baker simplifies the “counseling” requirement associat...Read More


Cann Trust - Sale and Investment Solicitation Process Free

 On March 31, 2020, CannTrust Holdings Inc. (the "Company") announced that the Company and certain of its subsidiaries (collectively, "CannTrust"...Read More


Cumberland Pharmaceuticals To Announce First Quarter 2020 Financial Results Free

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2020 financial results and a Company updat...Read More


Americas Gold And Silver Corporation Reports First Quarter 2020 Results Free

Americas Gold and Silver Corporation ("Americas" or the "Company") (TSX: USA; NYSE American: USAS), a growing North American precious metals prod...Read More